LAMB2 and cancer: We have previously reported that a laminin retreatment partially inhibited the binding of EGCG to the 67LR and treatment with the cell-surface LR-specific antibody MLuC5, capable of inhibiting laminin binding to 67LR, prevented EGCG’s abilities such as its cell-surface binding and inhibition of cancer cell growth [6].